Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has filed newspaper clippings with BSE showing that the extract of its unaudited standalone financial results for the quarter and half year ended 30 September 2025 was published on 15 November 2025 in The Business Standard (English) and The Nirbhaya Vaartha (Telugu), as required under SEBI LODR Regulation 47. For Q2 FY26, the company reported revenue from operations of Rs. 3,635.89 lakhs and profit after tax of Rs. 71.88 lakhs, with basic EPS of Rs. 0.55. For H1 FY26, total revenue stood at Rs. 5,874.26 lakhs versus Rs. 4,572.6 lakhs in H1 FY25, an increase of roughly 28% year-on-year. PAT for the half year rose sharply from Rs. 21.51 lakhs in H1 FY25 to Rs. 88.84 lakhs, more than a fourfold jump. The filing is signed by Whole-time Director Venkateshwarlu Pulluru.
This is essentially a routine compliance disclosure and is unlikely to move the stock on its own. However, the embedded numbers show strong YoY revenue growth and a sharp jump in half-yearly profit, which is a mildly positive signal pending the audited full-year results.